Atrial fibrillation and zoledronic acid in Paget's disease;Fibrilación auricular y ácido zoledrónico en la enfermedad de Paget

Reumatologia Clinica

Volumn 4, Issue 4, 2008, Pages 166-167

  Erra, Alba ^a   Moreno, Estefanía ^a   Rotés, Isabel ^a  

^a HOSPITAL SAN RAFAEL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID;

BONE NECROSIS; CLINICAL FEATURE; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HUMAN; HYPOCALCEMIA; LETTER; MAJOR CLINICAL STUDY; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; TREATMENT OUTCOME; VERTEBRA FRACTURE;

EID: 48649096488     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/S1699-258X(08)71828-X     Document Type: Letter

References (5)

1. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Onceyearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-22.
2. Cummings SR, Black DM, Thompson DE, Applegate WB, Barret-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-82.
3. Reid IR, Miller P, Lyles K, Fraser WD, Brown JP, Saidi Y, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med. 2005;353:898-908.
4. Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, et al. Longterm control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res. 2007;22:142-8.
5. Lyles K, Colon-Emeric C, Magaziner J, Adachi J, Pieper C, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799-809.